Yaneli Juárez-Vicuña
Research Subjects
Yaneli Juárez-Vicuña has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
- Fausto Sánchez-Muñoz
Departamento de Fisiología, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico
6 shared publications - Carlos Alfonso Guzmán-Martín
Doctorado en Ciencias Biológicas y de la Salud, Universidad Autónoma Metropolitana, Mexico City 04960, Mexico
4 shared publications - Luis Manuel Amezcua Guerra
Immunology Department, Instituto Nacional de Cardiología Ignacio Chávez , Mexico City , Mexico
4 shared publications - Adrián Hernández-Díazcouder
Unidad de Investigación Médica en Bioquímica, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City 06720, Mexico
3 shared publications - Laura Aline Martínez Martínez
Departamento de Reumatología, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City 14080, Mexico
3 shared publications - Alexandra Arias-Mendoza
Coronary Care Unit, National Institute of Cardiology, Mexico City, Mexico (A.A.-M.).
2 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1936710
N6-methyladenosine epitranscriptomic alterations and their potential implications for maternal–fetal immune tolerance in obstetric antiphospholipid syndrome
Obstetric antiphospholipid syndrome (OAPS) is an autoimmune disease characterized by the persistent presence of antiphospholipid antibodies (aPL), such as anticardiolipin and anti-β2-glycoprotein I antibodies, in women experiencing obstetric complications. While vascular thrombotic events were considered the primary pathogenic mechanism in recent years, evidence indicates that the maternal-fetal interface in OAPS is altered by other underlying pathways, such as direct impairment of trophoblast invasion, dysregulation of immune cell activation, and platelet complement activation. These pathways act synergistically to compromise the immunological tolerance essential for fetal development. In parallel, recent research has highlighted the role of epigenetic modifications that maintain placental homeostasis and trophoblast proliferation. N6-methyladenosine (m6A) is the most abundant messenger RNA (mRNA) modification in mammals and plays a fundamental role in the maternal-fetal interface and the generation of immune tolerance. Specifically, the upregulation of m6A-modulating proteins is associated with recurrent pregnancy loss, defective placental artery remodeling, and HLA-G expression, a key factor in fetomaternal tolerance. Despite this knowledge, to date, no review has integrated m6A modification as a key mediator in the loss of immune tolerance in the context of adverse obstetric outcomes, including fetal growth restriction (FGR). In this review, we proposing a hypothetical model in which aPL exposure could induce alterations in the m6A methylation pattern that may affect the HLA-G/regulatory T cells (Treg)/uterine NK cells (uNK) axis potentially contributing to fetal loss, operating independently or in conjunction with prothrombotic mechanisms.
- 29 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1936710
Open AccessN6-methyladenosine epitranscriptomic alterations and their potential implications for maternal–fetal immune tolerance in obstetric antiphospholipid syndrome
Obstetric antiphospholipid syndrome (OAPS) is an autoimmune disease characterized by the persistent presence of antiphospholipid antibodies (aPL), such as anticardiolipin and anti-β2-glycoprotein I antibodies, in women experiencing obstetric complications. While vascular thrombotic events were considered the primary pathogenic mechanism in recent years, evidence indicates that the maternal-fetal interface in OAPS is altered by other underlying pathways, such as direct impairment of trophoblast invasion, dysregulation of immune cell activation, and platelet complement activation. These pathways act synergistically to compromise the immunological tolerance essential for fetal development. In parallel, recent research has highlighted the role of epigenetic modifications that maintain placental homeostasis and trophoblast proliferation. N6-methyladenosine (m6A) is the most abundant messenger RNA (mRNA) modification in mammals and plays a fundamental role in the maternal-fetal interface and the generation of immune tolerance. Specifically, the upregulation of m6A-modulating proteins is associated with recurrent pregnancy loss, defective placental artery remodeling, and HLA-G expression, a key factor in fetomaternal tolerance. Despite this knowledge, to date, no review has integrated m6A modification as a key mediator in the loss of immune tolerance in the context of adverse obstetric outcomes, including fetal growth restriction (FGR). In this review, we proposing a hypothetical model in which aPL exposure could induce alterations in the m6A methylation pattern that may affect the HLA-G/regulatory T cells (Treg)/uterine NK cells (uNK) axis potentially contributing to fetal loss, operating independently or in conjunction with prothrombotic mechanisms.
- Open Access
- 29 October 2026
- Published by Taylor & Francis in Autoimmunity
- Vol. 59 (1)
CXCL13 rs355687 variant confers increased susceptibility to systemic lupus erythematosus in a Mexican population
Chemokines are a family of structurally related, low-molecular-weight proteins (8–14 kDa) that regulate leukocyte recruitment under both homeostatic and pathological conditions, including infection...
- 29 October 2026
- Published by Taylor & Francis in Autoimmunity
- Vol. 59 (1)
Open AccessCXCL13 rs355687 variant confers increased susceptibility to systemic lupus erythematosus in a Mexican population
Chemokines are a family of structurally related, low-molecular-weight proteins (8–14 kDa) that regulate leukocyte recruitment under both homeostatic and pathological conditions, including infection...
- Open Access
- 1 September 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (9) , 1263
BRD3OS Dysregulation in Antiphospholipid Syndrome: Integrative Network and RNA Structural Analysis of m6A-Related Candidate Regions
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by thrombotic and inflammatory manifestations whose molecular regulatory mechanisms remain incompletely understood. Long non-coding RNAs (lncRNAs) and N6-methyladenosine (m6A)-related regulation are increasingly recognized as components of immune gene regulation, but their involvement in APS remains poorly characterized. This study investigated BRD3OS (LINC00094) expression in APS and explored its molecular and predicted structural context in relation to m6A-associated regulation. An exploratory case–control study was conducted using an initial lncRNA PCR-array discovery cohort followed by targeted RT-qPCR validation in an independent cohort. Candidate prioritization incorporated multiple expression and technical features and was evaluated through sensitivity analyses. BRD3OS expression, selected m6A regulators (METTL3, METTL14, WTAP, and FTO), inflammatory mediators, and global m6A abundance in total peripheral blood mononuclear cell (PBMC) RNA were evaluated. Bioinformatic network analysis was used to contextualize BRD3OS within APS- and m6A-related molecular systems. RNAfold and RNAplfold were used to characterize the predicted structural context and accessibility of DRACH consensus motifs, with additional analyses evaluating fragment-boundary and composite-score robustness. BRD3OS was significantly downregulated in PBMCs from patients with APS in the independent validation cohort. METTL3, METTL14, and WTAP expression was also reduced, whereas global m6A levels in total PBMC RNA were increased. These observations indicate concurrent alterations in BRD3OS expression and the broader m6A-related molecular environment but do not establish transcript-specific methylation of BRD3OS. Bioinformatic network analysis placed BRD3OS within predicted RNA-centered regulatory relationships relevant to APS. DRACH motifs exhibited heterogeneous predicted structural accessibility, with unpaired structural environments showing greater RNAplfold-derived accessibility than paired regions. Quantitative accessibility estimates were highly concordant across overlapping transcript fragments, although sensitivity analyses indicated that the identity of individual highest-ranked candidates depended on the weighting scheme. BRD3OS downregulation represents a reproducible molecular finding in APS. Concurrent alterations in global m6A abundance and selected m6A regulators suggest broader epitranscriptomic dysregulation; however, these measurements cannot establish m6A modification of BRD3OS or a causal relationship between these observations. Structural and network analyses therefore provide a hypothesis-generating framework for prioritizing candidate regions and interactions for future transcript-specific methylation mapping and functional validation.
- 1 September 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (9) , 1263
Open AccessBRD3OS Dysregulation in Antiphospholipid Syndrome: Integrative Network and RNA Structural Analysis of m6A-Related Candidate Regions
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by thrombotic and inflammatory manifestations whose molecular regulatory mechanisms remain incompletely understood. Long non-coding RNAs (lncRNAs) and N6-methyladenosine (m6A)-related regulation are increasingly recognized as components of immune gene regulation, but their involvement in APS remains poorly characterized. This study investigated BRD3OS (LINC00094) expression in APS and explored its molecular and predicted structural context in relation to m6A-associated regulation. An exploratory case–control study was conducted using an initial lncRNA PCR-array discovery cohort followed by targeted RT-qPCR validation in an independent cohort. Candidate prioritization incorporated multiple expression and technical features and was evaluated through sensitivity analyses. BRD3OS expression, selected m6A regulators (METTL3, METTL14, WTAP, and FTO), inflammatory mediators, and global m6A abundance in total peripheral blood mononuclear cell (PBMC) RNA were evaluated. Bioinformatic network analysis was used to contextualize BRD3OS within APS- and m6A-related molecular systems. RNAfold and RNAplfold were used to characterize the predicted structural context and accessibility of DRACH consensus motifs, with additional analyses evaluating fragment-boundary and composite-score robustness. BRD3OS was significantly downregulated in PBMCs from patients with APS in the independent validation cohort. METTL3, METTL14, and WTAP expression was also reduced, whereas global m6A levels in total PBMC RNA were increased. These observations indicate concurrent alterations in BRD3OS expression and the broader m6A-related molecular environment but do not establish transcript-specific methylation of BRD3OS. Bioinformatic network analysis placed BRD3OS within predicted RNA-centered regulatory relationships relevant to APS. DRACH motifs exhibited heterogeneous predicted structural accessibility, with unpaired structural environments showing greater RNAplfold-derived accessibility than paired regions. Quantitative accessibility estimates were highly concordant across overlapping transcript fragments, although sensitivity analyses indicated that the identity of individual highest-ranked candidates depended on the weighting scheme. BRD3OS downregulation represents a reproducible molecular finding in APS. Concurrent alterations in global m6A abundance and selected m6A regulators suggest broader epitranscriptomic dysregulation; however, these measurements cannot establish m6A modification of BRD3OS or a causal relationship between these observations. Structural and network analyses therefore provide a hypothesis-generating framework for prioritizing candidate regions and interactions for future transcript-specific methylation mapping and functional validation.
- Open Access
- 14 January 2026
- Published by MDPI AG in Preprints.org
Dysregulation of the MEG3–ATF4 Axis in ST-Segment Elevation Myocardial Infarction: A Proof-of-Concept Study
Background/Objectives: Cardiovascular disease is the leading cause of morbidity and mortality worldwide, of which the myocardial Infarction is the most prevalent. However, the underlying pathophysiological mechanisms remain incompletely understood, but are tightly regulated by several cellular mechanisms, including long-non-coding. This study aimed to determine if MEG3 and ATF4 are involved in this pathology. Methods: A cross-section study was conducted at the Instituto Nacional de Cardiología Ignacio Chávez, patients with first time diagnosis STEMI and hemodynamic stability were categorized into with and without major adverse cardiovascular events, the most important clinical and biochemical parameters were collected, which were analyzed and subsequently correlated with MEG3 and ATF4. Results: Forty-two patients with a median age of 54 years (86% men) were included and classified with and without MACE. The expression of MEG3 in MACE group and No MACE (0.8974, 0.4186–1.4131 vs. 1.2259, 0.5516–2.3964; p = 0.0342), and ATF4 in MACE group and No MACE (2.8950, 0.7559–4.3287 vs. 2.3498, 1.0821–3.6903; p = 0.0396), ROC curve MEG3 showed an AUC of 0.6490 (0.4760 to 0.8221; p = 0.0924), in contrast ATF4 demonstrated an AUC of 0.7127 (0.5862 to 0.8393; p = 0.0107). Finally, correlation analyses revealed MEG3 was associated with CK-MB (r = 0.3978, 0.0630 to 0.6520; p = 0.0219), and ATF4 was correlated cTnT (r = 0.3328, 0.0284 to 0.5810; p = 0.0335) and with LVEF (r = –0.4283, –0.6503 to –0.1390; p = 0.0052). Conclusions: The dysregulation of MEG3 and transcription factor ATF4 are involved in pathophysiological mechanisms.
- 14 January 2026
- Published by MDPI AG in Preprints.org
Open AccessDysregulation of the MEG3–ATF4 Axis in ST-Segment Elevation Myocardial Infarction: A Proof-of-Concept Study
Background/Objectives: Cardiovascular disease is the leading cause of morbidity and mortality worldwide, of which the myocardial Infarction is the most prevalent. However, the underlying pathophysiological mechanisms remain incompletely understood, but are tightly regulated by several cellular mechanisms, including long-non-coding. This study aimed to determine if MEG3 and ATF4 are involved in this pathology. Methods: A cross-section study was conducted at the Instituto Nacional de Cardiología Ignacio Chávez, patients with first time diagnosis STEMI and hemodynamic stability were categorized into with and without major adverse cardiovascular events, the most important clinical and biochemical parameters were collected, which were analyzed and subsequently correlated with MEG3 and ATF4. Results: Forty-two patients with a median age of 54 years (86% men) were included and classified with and without MACE. The expression of MEG3 in MACE group and No MACE (0.8974, 0.4186–1.4131 vs. 1.2259, 0.5516–2.3964; p = 0.0342), and ATF4 in MACE group and No MACE (2.8950, 0.7559–4.3287 vs. 2.3498, 1.0821–3.6903; p = 0.0396), ROC curve MEG3 showed an AUC of 0.6490 (0.4760 to 0.8221; p = 0.0924), in contrast ATF4 demonstrated an AUC of 0.7127 (0.5862 to 0.8393; p = 0.0107). Finally, correlation analyses revealed MEG3 was associated with CK-MB (r = 0.3978, 0.0630 to 0.6520; p = 0.0219), and ATF4 was correlated cTnT (r = 0.3328, 0.0284 to 0.5810; p = 0.0335) and with LVEF (r = –0.4283, –0.6503 to –0.1390; p = 0.0052). Conclusions: The dysregulation of MEG3 and transcription factor ATF4 are involved in pathophysiological mechanisms.
- Open Access
- 1 January 2026
- Published by BMJ in Lupus Science & Medicine
- Vol. 13 (1) , e001878
Baseline characteristics of patients with SLE with and without lupus nephritis from the Latin American multiethnic GLADEL 2.0 cohort
Objective: To describe baseline characteristics of a multinational, multiethnic Latin American cohort of SLE patients with and without lupus nephritis (LN) from Latin American Group for the Study of Lupus (GLADEL) 2.0. Methods: GLADEL 2.0 is an observational prevalent and incident cohort. Adult patients (≥18 years) with SLE who fulfilled the 1982/1997 American College of Rheumatology (ACR) and/or the 2012 Systemic Lupus International Collaborating Clinics (SLICC) classification criteria from 43 centres in 10 Latin American countries were categorised into four groups: (1) without LN, (2) prevalent inactive LN, (3) prevalent active LN and (4) incident LN. Baseline demographics, clinical manifestations, treatments, disease activity and damage were recorded. A cross-sectional analysis and logistic regression was conducted to identify factors associated with LN and cumulative damage (SLICC/ACR Damage Index (SDI)). Results: Among 1083 patients, 89.6% were female, median age at diagnosis was 27 years, median disease duration was 66.2 months and 65.0% were Mestizo. Patients with LN (n=653) were younger and had shorter disease duration than patients without LN. LN was negatively associated with older age at diagnosis (OR, 0.98) and discoid rash (OR, 0.53) and positively associated with male gender (OR, 1.91), Mestizo ethnicity (OR, 1.46), comorbidities (OR, 3.2), thrombocytopenia (OR, 3.44), anti–double-stranded DNA (anti-dsDNA) positivity (OR, 3.23) and low complement (OR, 1.54). SDI ≥1 was associated with older age at diagnosis, longer disease duration, cumulative prednisone dose and cyclophosphamide use. Conclusions: Male sex, Mestizo ethnicity, comorbidities, thrombocytopenia, anti-dsDNA positivity and low complement levels were associated with LN occurrence. Cumulative damage was associated with older age at diagnosis, longer disease duration, higher cumulative dose of prednisone and the use of cyclophosphamide. Trial registration number: NCT04534647 .
- 1 January 2026
- Published by BMJ in Lupus Science & Medicine
- Vol. 13 (1) , e001878
Open AccessBaseline characteristics of patients with SLE with and without lupus nephritis from the Latin American multiethnic GLADEL 2.0 cohort
Objective: To describe baseline characteristics of a multinational, multiethnic Latin American cohort of SLE patients with and without lupus nephritis (LN) from Latin American Group for the Study of Lupus (GLADEL) 2.0. Methods: GLADEL 2.0 is an observational prevalent and incident cohort. Adult patients (≥18 years) with SLE who fulfilled the 1982/1997 American College of Rheumatology (ACR) and/or the 2012 Systemic Lupus International Collaborating Clinics (SLICC) classification criteria from 43 centres in 10 Latin American countries were categorised into four groups: (1) without LN, (2) prevalent inactive LN, (3) prevalent active LN and (4) incident LN. Baseline demographics, clinical manifestations, treatments, disease activity and damage were recorded. A cross-sectional analysis and logistic regression was conducted to identify factors associated with LN and cumulative damage (SLICC/ACR Damage Index (SDI)). Results: Among 1083 patients, 89.6% were female, median age at diagnosis was 27 years, median disease duration was 66.2 months and 65.0% were Mestizo. Patients with LN (n=653) were younger and had shorter disease duration than patients without LN. LN was negatively associated with older age at diagnosis (OR, 0.98) and discoid rash (OR, 0.53) and positively associated with male gender (OR, 1.91), Mestizo ethnicity (OR, 1.46), comorbidities (OR, 3.2), thrombocytopenia (OR, 3.44), anti–double-stranded DNA (anti-dsDNA) positivity (OR, 3.23) and low complement (OR, 1.54). SDI ≥1 was associated with older age at diagnosis, longer disease duration, cumulative prednisone dose and cyclophosphamide use. Conclusions: Male sex, Mestizo ethnicity, comorbidities, thrombocytopenia, anti-dsDNA positivity and low complement levels were associated with LN occurrence. Cumulative damage was associated with older age at diagnosis, longer disease duration, higher cumulative dose of prednisone and the use of cyclophosphamide. Trial registration number: NCT04534647 .
- Open Access
- 1 June 2024
- Published by KEAI Publishing in Non-coding RNA Research
- Vol. 9 (2) , 594-601
LncRNA MALAT1 in Keratinocyte function: A review of recent advances
Keratinocytes, the principal epidermal cells, play a vital role in maintaining the structural integrity and functionality of the skin. Beyond their protective role, keratinocytes are key contributors to the process of wound healing, as they migrate to injury sites, proliferate, and generate new layers of epidermis, facilitating tissue repair and remodeling. Moreover, keratinocytes actively participate in the skin's immune responses, expressing pattern recognition receptors (PRRs) to detect microbial components and interact with immune cells to influence adaptive immunity. Keratinocytes express a diverse repertoire of signaling pathways, transcription factors, and epigenetic regulators to regulate their growth, differentiation, and response to environmental cues. Among these regulatory elements, long non-coding RNAs (lncRNAs) have emerged as essential players in keratinocyte biology. LncRNAs, including MALAT1, play diverse roles in gene regulation and cellular processes, influencing keratinocyte proliferation, differentiation, migration, and response to environmental stimuli. Dysregulation of specific lncRNAs such as MALAT1 can disrupt keratinocyte homeostasis, leading to impaired differentiation, compromised barrier integrity, and contributing to the pathogenesis of various skin disorders. Understanding the intricate interplay between lncRNAs and keratinocytes offers promising insights into the molecular underpinnings of skin health and disease, with potential implications for targeted therapies and advancements in dermatological research. Hence, our objective is to provide a comprehensive summary of the available knowledge concerning keratinocytes and their intricate relationship with MALAT1.
- 1 June 2024
- Published by KEAI Publishing in Non-coding RNA Research
- Vol. 9 (2) , 594-601
Open AccessLncRNA MALAT1 in Keratinocyte function: A review of recent advances
Keratinocytes, the principal epidermal cells, play a vital role in maintaining the structural integrity and functionality of the skin. Beyond their protective role, keratinocytes are key contributors to the process of wound healing, as they migrate to injury sites, proliferate, and generate new layers of epidermis, facilitating tissue repair and remodeling. Moreover, keratinocytes actively participate in the skin's immune responses, expressing pattern recognition receptors (PRRs) to detect microbial components and interact with immune cells to influence adaptive immunity. Keratinocytes express a diverse repertoire of signaling pathways, transcription factors, and epigenetic regulators to regulate their growth, differentiation, and response to environmental cues. Among these regulatory elements, long non-coding RNAs (lncRNAs) have emerged as essential players in keratinocyte biology. LncRNAs, including MALAT1, play diverse roles in gene regulation and cellular processes, influencing keratinocyte proliferation, differentiation, migration, and response to environmental stimuli. Dysregulation of specific lncRNAs such as MALAT1 can disrupt keratinocyte homeostasis, leading to impaired differentiation, compromised barrier integrity, and contributing to the pathogenesis of various skin disorders. Understanding the intricate interplay between lncRNAs and keratinocytes offers promising insights into the molecular underpinnings of skin health and disease, with potential implications for targeted therapies and advancements in dermatological research. Hence, our objective is to provide a comprehensive summary of the available knowledge concerning keratinocytes and their intricate relationship with MALAT1.
- Open Access
- 25 October 2023
- Published by BMJ in Lupus Science & Medicine
- Vol. 10 (2) , e000970
Mononuclear cells from patients with rhupus are influenced by TNF in their production of gp130/sIL-6Rb and APRIL
Objective Rhupus is a rare disease that shares characteristics of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). While several studies have explored the clinical and immunological profiles of patients with rhupus, the underlying cause of the disease remains unknown due to its complex pathogenesis. The objective of this study was to investigate the role of tumour necrosis factor (TNF) in the production of inflammatory molecules by peripheral blood mononuclear cells (PBMCs) from patients with rhupus. Methods The study involved five healthy controls, seven patients with rhupus and seven patients with SLE. PBMCs were obtained from each participant and stimulated with recombinant human TNF for 24 hours. The levels of various molecules secreted by the cells, such as cytokines and chemokines, were measured using immunobead-based assays on xMAP technology. Results The production levels of some molecules were higher in TNF-stimulated PBMCs from patients with rhupus and SLE than in unstimulated cells. In addition, the levels of certain molecules, including gp130/sIL-6Rb, a proliferation-inducing ligand (APRIL), interferon-β, matrix metalloproteinase-3 and interleukin (IL)-12, were higher in PBMCs from patients with rhupus even without TNF stimulation. Similarly, the levels of gp130/sIL-6Rb and APRIL were higher in TNF-stimulated PBMCs from patients with rhupus than in healthy controls. These results were further validated against patients with RA using enzyme-linked immunosorbent assay. Conclusions These findings suggest that the spontaneous production of molecules by cells from patients with rhupus may contribute to the development of the disease, and that TNF may play a role in this process by regulating the secretion of gp130/sIL-6Rb and APRIL.
- 25 October 2023
- Published by BMJ in Lupus Science & Medicine
- Vol. 10 (2) , e000970
Open AccessMononuclear cells from patients with rhupus are influenced by TNF in their production of gp130/sIL-6Rb and APRIL
Objective Rhupus is a rare disease that shares characteristics of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). While several studies have explored the clinical and immunological profiles of patients with rhupus, the underlying cause of the disease remains unknown due to its complex pathogenesis. The objective of this study was to investigate the role of tumour necrosis factor (TNF) in the production of inflammatory molecules by peripheral blood mononuclear cells (PBMCs) from patients with rhupus. Methods The study involved five healthy controls, seven patients with rhupus and seven patients with SLE. PBMCs were obtained from each participant and stimulated with recombinant human TNF for 24 hours. The levels of various molecules secreted by the cells, such as cytokines and chemokines, were measured using immunobead-based assays on xMAP technology. Results The production levels of some molecules were higher in TNF-stimulated PBMCs from patients with rhupus and SLE than in unstimulated cells. In addition, the levels of certain molecules, including gp130/sIL-6Rb, a proliferation-inducing ligand (APRIL), interferon-β, matrix metalloproteinase-3 and interleukin (IL)-12, were higher in PBMCs from patients with rhupus even without TNF stimulation. Similarly, the levels of gp130/sIL-6Rb and APRIL were higher in TNF-stimulated PBMCs from patients with rhupus than in healthy controls. These results were further validated against patients with RA using enzyme-linked immunosorbent assay. Conclusions These findings suggest that the spontaneous production of molecules by cells from patients with rhupus may contribute to the development of the disease, and that TNF may play a role in this process by regulating the secretion of gp130/sIL-6Rb and APRIL.
- Open Access
- 30 August 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (9) , 2422
Diagnostic Performance of Serum MicroRNAs for ST-Segment Elevation Myocardial Infarction in the Emergency Department
Prompt diagnosis of ST-segment elevation myocardial infarction (STEMI) is essential for initiating timely treatment. MicroRNAs have recently emerged as biomarkers in cardiovascular diseases. This study aimed to evaluate the discriminatory capacity of serum microRNAs in identifying an ischemic origin in patients presenting with chest discomfort to the Emergency Department. The study included 98 participants (78 with STEMI and 20 with nonischemic chest discomfort). Significant differences in the expression levels of miR-133b, miR-126, and miR-155 (but not miR-1, miR-208, and miR-208b) were observed between groups. miR-133b and miR-155 exhibited 97% and 93% sensitivity in identifying STEMI patients, respectively. miR-126 demonstrated a specificity of 90% in identifying STEMI patients. No significant associations were found between microRNAs and occurrence of major adverse cardiovascular events (MACE). However, patients with MACE had higher levels of interleukin (IL)-15, IL-21, IFN-γ-induced protein-10, and N-terminal pro B-type natriuretic peptide compared to non-MACE patients. Overall, there were significant associations among the expression levels of microRNAs. However, microRNAs did not demonstrate associations with either inflammatory markers or cardiovascular risk scores. This study highlights the potential of microRNAs, particularly miR-133b and miR-126, as diagnostic biomarkers for distinguishing patients with STEMI from those presenting with nonischemic chest discomfort to the Emergency Department.
- 30 August 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (9) , 2422
Open AccessDiagnostic Performance of Serum MicroRNAs for ST-Segment Elevation Myocardial Infarction in the Emergency Department
Prompt diagnosis of ST-segment elevation myocardial infarction (STEMI) is essential for initiating timely treatment. MicroRNAs have recently emerged as biomarkers in cardiovascular diseases. This study aimed to evaluate the discriminatory capacity of serum microRNAs in identifying an ischemic origin in patients presenting with chest discomfort to the Emergency Department. The study included 98 participants (78 with STEMI and 20 with nonischemic chest discomfort). Significant differences in the expression levels of miR-133b, miR-126, and miR-155 (but not miR-1, miR-208, and miR-208b) were observed between groups. miR-133b and miR-155 exhibited 97% and 93% sensitivity in identifying STEMI patients, respectively. miR-126 demonstrated a specificity of 90% in identifying STEMI patients. No significant associations were found between microRNAs and occurrence of major adverse cardiovascular events (MACE). However, patients with MACE had higher levels of interleukin (IL)-15, IL-21, IFN-γ-induced protein-10, and N-terminal pro B-type natriuretic peptide compared to non-MACE patients. Overall, there were significant associations among the expression levels of microRNAs. However, microRNAs did not demonstrate associations with either inflammatory markers or cardiovascular risk scores. This study highlights the potential of microRNAs, particularly miR-133b and miR-126, as diagnostic biomarkers for distinguishing patients with STEMI from those presenting with nonischemic chest discomfort to the Emergency Department.
- 11 November 2022
- Published by Springer Nature in Molecular Biology Reports
- Vol. 50 (1) , 937-941
lncRNAs dysregulation in monocytes from primary antiphospholipid syndrome patients: a bioinformatic and an experimental proof-of-concept approach
Background Antiphospholipid syndrome (APS) is the main cause of acquired thrombophilia where peripheral circulating cells such as monocytes have a key role. Currently, several studies have linked long non-coding RNAs (lncRNAs) in different inflammatory and autoimmune processes, including lupus. However, the role of lncRNAs in antiphospholipid syndrome is unknown, therefore, we aimed to select and measure expression levels of three lncRNAs based on its abundance in monocytes from APS patients. Methods Selection of lncRNAs candidates were carried out based on its abundance in monocytes and their relationship with Perez-Sanchez miRNA signature by using miRNet 2.0 bioinformatic tool, then lncRNAs expression levels was measured in monocytes by RT-qPCR. Results This is the first study to report that lncRNAs: FGD5-AS1, OIP5-AS1 and GAS5 are promising candidates for play a role on APS monocytes and they are expressed differently between patients and controls. Conclusions OIP5-AS1, FGD5-AS1 and GAS5 are downregulated on monocytes from APS patients.
- 11 November 2022
- Published by Springer Nature in Molecular Biology Reports
- Vol. 50 (1) , 937-941
lncRNAs dysregulation in monocytes from primary antiphospholipid syndrome patients: a bioinformatic and an experimental proof-of-concept approach
Background Antiphospholipid syndrome (APS) is the main cause of acquired thrombophilia where peripheral circulating cells such as monocytes have a key role. Currently, several studies have linked long non-coding RNAs (lncRNAs) in different inflammatory and autoimmune processes, including lupus. However, the role of lncRNAs in antiphospholipid syndrome is unknown, therefore, we aimed to select and measure expression levels of three lncRNAs based on its abundance in monocytes from APS patients. Methods Selection of lncRNAs candidates were carried out based on its abundance in monocytes and their relationship with Perez-Sanchez miRNA signature by using miRNet 2.0 bioinformatic tool, then lncRNAs expression levels was measured in monocytes by RT-qPCR. Results This is the first study to report that lncRNAs: FGD5-AS1, OIP5-AS1 and GAS5 are promising candidates for play a role on APS monocytes and they are expressed differently between patients and controls. Conclusions OIP5-AS1, FGD5-AS1 and GAS5 are downregulated on monocytes from APS patients.
- 6 May 2022
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
- Vol. 40 (12) , 2275-2282
Interferon-alpha regulates expression of lncRNA MALAT1 and interferon-stimulated genes, as well as chemokine production, in primary Sjögren's syndrome
Full Papers; Authors: L.M. Amezcua-Guerra, F. Sánchez-Muñoz, E. Pichardo-Ontiveros, J. González-Ramírez, L.A. Martínez-Martínez, Y. Juárez-Vicuña
- 6 May 2022
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
- Vol. 40 (12) , 2275-2282
Interferon-alpha regulates expression of lncRNA MALAT1 and interferon-stimulated genes, as well as chemokine production, in primary Sjögren's syndrome
Full Papers; Authors: L.M. Amezcua-Guerra, F. Sánchez-Muñoz, E. Pichardo-Ontiveros, J. González-Ramírez, L.A. Martínez-Martínez, Y. Juárez-Vicuña